Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens.

Journal: HIV research & clinical practice
PMID: 32000615

Abstract

To understand the pathogenesis of low level viraemia (LLV) in HIV-infected patients on boosted protease inhibitors (PI/b), we enrolled 34 subjects with a median HIV-RNA 79 copies/mL and followed them for 15 months. Samples for next generation sequencing were collected at three time-points. Two showed resistance-associated mutations (RAMs) in the protease gene, while 95-100% had RAMs in the gag gene, which evolved in approximately a quarter of subjects, suggesting a potential clinical role of these kind of mutations.

Authors

  • Francesca Ferretti
    Department of HIV, Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
  • Nicola E Mackie
    Department of HIV, Sexual Health and Infections, Imperial College Healthcare NHS Trust, London, UK.
  • Gurmit Kaur Jagjit Singh
    Department of HIV, Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
  • Julie Fox
    Guy's and St Thomas Hospital NHS Foundation Trust, London, UK.
  • Steve Kaye
    Division of Infectious Diseases, Imperial College London, London, UK.
  • Myra O McClure
    Division of Infectious Diseases, Imperial College London, London, UK.
  • Graham Taylor
    Division of Infectious Diseases, Imperial College London, London, UK.
  • Marta Boffito
    Department of HIV, Sexual Health, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.

Keywords

External Resources

Popular Topics
Recent Journals